D'Orazi V - Search Results

1

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.

Garufi A, Baldari S, Pettinari R, Gilardini Montani MS, D'Orazi V, Pistritto G, Crispini A, Giorno E, Toietta G, Marchetti F, Cirone M, D'Orazi G. Garufi A, et al. J Exp Clin Cancer Res. 2020 Jun 30;39(1):122. doi: 10.1186/s13046-020-01628-5. J Exp Clin Cancer Res. 2020. PMID: 32605658 Free PMC article.

2

A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.

Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D'Orazi V, Avantaggiati M, Crispini A, Pucci D, D'Orazi G. Garufi A, et al. J Exp Clin Cancer Res. 2013 Oct 7;32(1):72. doi: 10.1186/1756-9966-32-72. J Exp Clin Cancer Res. 2013. PMID: 24220325 Free PMC article.

3

Gentian violet induces wtp53 transactivation in cancer cells.

Garufi A, D'Orazi V, Arbiser JL, D'Orazi G. Garufi A, et al. Int J Oncol. 2014 Apr;44(4):1084-90. doi: 10.3892/ijo.2014.2304. Epub 2014 Feb 14. Int J Oncol. 2014. PMID: 24535435 Free PMC article.

4

Degradation of mutant p53H175 protein by Zn(II) through autophagy.

Garufi A, Pucci D, D'Orazi V, Cirone M, Bossi G, Avantaggiati ML, D'Orazi G. Garufi A, et al. Cell Death Dis. 2014 May 29;5(5):e1271. doi: 10.1038/cddis.2014.217. Cell Death Dis. 2014. PMID: 24874727 Free PMC article.

5

The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells.

Garufi A, Ubertini V, Mancini F, D'Orazi V, Baldari S, Moretti F, Bossi G, D'Orazi G. Garufi A, et al. J Exp Clin Cancer Res. 2015 Aug 22;34(1):87. doi: 10.1186/s13046-015-0206-x. J Exp Clin Cancer Res. 2015. PMID: 26297485 Free PMC article.

6

Zn(II)-curc targets p53 in thyroid cancer cells.

Garufi A, D'Orazi V, Crispini A, D'Orazi G. Garufi A, et al. Int J Oncol. 2015 Oct;47(4):1241-8. doi: 10.3892/ijo.2015.3125. Epub 2015 Aug 13. Int J Oncol. 2015. PMID: 26314369 Free PMC article.

7

Reduced chemotherapeutic sensitivity in high glucose condition: implication of antioxidant response.

Garufi A, Traversi G, Gilardini Montani MS, D'Orazi V, Pistritto G, Cirone M, D'Orazi G. Garufi A, et al. Oncotarget. 2019 Jul 23;10(45):4691-4702. doi: 10.18632/oncotarget.27087. eCollection 2019 Jul 23. Oncotarget. 2019. PMID: 31384396 Free PMC article.

8

The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study.

Garufi A, Pistritto G, D'Orazi V, Cirone M, D'Orazi G. Garufi A, et al. Among authors: d orazi v. Biomolecules. 2022 Mar 17;12(3):461. doi: 10.3390/biom12030461. Biomolecules. 2022. PMID: 35327653 Free PMC article.

9

HIPK2 in Angiogenesis: A Promising Biomarker in Cancer Progression and in Angiogenic Diseases.

Garufi A, D'Orazi V, Pistritto G, Cirone M, D'Orazi G. Garufi A, et al. Among authors: d orazi v. Cancers (Basel). 2023 Mar 2;15(5):1566. doi: 10.3390/cancers15051566. Cancers (Basel). 2023. PMID: 36900356 Free PMC article. Review.

10

The Sweet Side of HIPK2.

Garufi A, D'Orazi V, Pistritto G, Cirone M, D'Orazi G. Garufi A, et al. Among authors: d orazi v. Cancers (Basel). 2023 May 9;15(10):2678. doi: 10.3390/cancers15102678. Cancers (Basel). 2023. PMID: 37345014 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters